SEARCH

SEARCH BY CITATION

References

  • Augood S. J., Faull R. L. and Emson P. C. (1997a) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 42, 215221.
  • Augood S. J., Westmore K. and Emson P. C. (1997b) Phenotypic characterization of neurotensin messenger RNA-expressing cells in the neuroleptic-treated rat striatum: a detailed cellular co-expression study. Neuroscience 76, 763774.
  • Bak M., Silahtaroglu A., Moller M., Christensen M., Rath M. F., Skryabin B., Tommerup N. and Kauppinen S. (2008) MicroRNA expression in the adult mouse central nervous system. RNA 14, 432444.
  • Balastik M., Ferraguti F., Pires-da Silva A., Lee T. H., Alvarez-Bolado G., Lu K. P. and Gruss P. (2008) Deficiency in ubiquitin ligase TRIM2 causes accumulation of neurofilament light chain and neurodegeneration. Proc. Natl Acad. Sci. USA 105, 1201612021.
  • Barton W. A., Liu B. P., Tzvetkova D., Jeffrey P. D., Fournier A. E., Sah D., Cate R., Strittmatter S. M. and Nikolov D. B. (2003) Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. EMBO J. 22, 32913302.
  • Bilen J., Liu N. and Bonini N. M. (2006) A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle 5, 28352838.
  • Butz S., Okamoto M. and Sudhof T. C. (1998) A tripartite protein complex with the potential to couple synaptic vesicle exocytosis to cell adhesion in brain. Cell 94, 773782.
  • Cattaneo E., Zuccato C. and Tartari M. (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6, 919930.
  • Chamberlain L. H., Graham M. E., Kane S., Jackson J. L., Maier V. H., Burgoyne R. D. and Gould G. W. (2001) The synaptic vesicle protein, cysteine-string protein, is associated with the plasma membrane in 3T3-L1 adipocytes and interacts with syntaxin 4. J. Cell Sci. 114, 445455.
  • Cheng Y., Peng Q., Hou Z., Aggarwal M., Zhang J., Mori S., Ross C. A. and Duan W. (2011) Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171–82Q Huntington's disease mouse model. Neuroimage 56, 10271034.
  • Choi P. S., Zakhary L., Choi W. Y. et al. (2008) Members of the miRNA-200 family regulate olfactory neurogenesis. Neuron 57, 4155.
  • Chung C. Y., Koprich J. B., Siddiqi H. and Isacson O. (2009) Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 29, 33653373.
  • Conrad R., Barrier M. and Ford L. P. (2006) Role of miRNA and miRNA processing factors in development and disease. Birth Defects Res. C Embryo Today 78, 107117.
  • Crook Z. R. and Housman D. E. (2012) Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice. Proc. Natl Acad. Sci. USA 109, 74877492.
  • Cuellar T. L., Davis T. H., Nelson P. T., Loeb G. B., Harfe B. D., Ullian E. and McManus M. T. (2008) Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration. Proc. Natl Acad. Sci. USA 105, 56145619.
  • Cunningham J. M., Oberg A. L., Borralho P. M. et al. (2009) Evaluation of a new high-dimensional miRNA profiling platform. BMC Med. Genomics 2, 57.
  • Dodson P. D., Barker M. C. and Forsythe I. D. (2002) Two heteromeric Kv1 potassium channels differentially regulate action potential firing. J. Neurosci. 22, 69536961.
  • Dodson P. D., Billups B., Rusznak Z., Szucs G., Barker M. C. and Forsythe I. D. (2003) Presynaptic rat Kv1.2 channels suppress synaptic terminal hyperexcitability following action potential invasion. J. Physiol. 550, 2733.
  • Duan W., Guo Z., Jiang H., Ware M. and Mattson M. P. (2003) Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 144, 24462453.
  • Duan W., Peng Q., Masudaa N., Ford E., Tryggestad E., Ladenheim B., Zhao M., cadet J. L., Wong J. and Ross C. A. (2008) Sertraline slows disease progression and increases neurogenesis in N171–82Q mouse model of Huntington's disease. Neurobiol. Dis. 30, 312322.
  • Etherton M. R., Blaiss C. A., Powell C. M. and Sudhof T. C. (2009) Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc. Natl Acad. Sci. USA 106, 1799818003.
  • Fairless R., Masius H., Rohlmann A., Heupel K., Ahmad M., Reissner C., Dresbach T. and Missler M. (2008) Polarized targeting of neurexins to synapses is regulated by their C-terminal sequences. J. Neurosci. 28, 1296912981.
  • Ferrante R. J., Gutekunst C. A., Persichetti F., McNeil S. M., Kowall N. W., Gusella J. F., MacDonald M. E., Beal M. F. and Hersch S. M. (1997) Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 17, 30523063.
  • Fusco F. R., Chen Q., Lamoreaux W. J. II, Figueredo-Cardenas G., Jiao Y., Coffman J. A., Surmeier D. J., Honig M. G., Carlock L. R. and Reiner A. (1999) Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J. Neurosci. 19, 11891202.
  • Goold R., Hubank M., Hunt A., Holton J., Menon R. P., Revesz T., Pandolfo M. and Matilla-Duenas A. (2007) Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. Hum. Mol. Genet. 16, 21222134.
  • Gray S. G. (2011) Targeting Huntington's disease through histone deacetylases. Clin. Epigenetics 2, 257277.
  • Grimson A., Farh K. K., Johnston W. K., Garrett-Engele P., Lim L. P. and Bartel D. P. (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91105.
  • Guillerme-Bosselut F., Forestier L., Jayat-Vignoles C., Vilotte J., Popa I., Portoukalian J., Le Dur A., Laude H., Julien R. and Gallet P. F. (2009) Glycosylation-related gene expression profiling in the brain and spleen of scrapie-affected mouse. Glycobiology 19, 879889.
  • Hodges A., Strand A. D., Aragaki A. K. et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 15, 965977.
  • Johnson R., Zuccato C., Belyaev N. D., Guest D. J., Cattaneo E. and Buckley N. J. (2008) A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol. Dis. 29, 438445.
  • Khazaei M. R., Bunk E. C., Hillje A. L., Jahn H. M., Riegler E. M., Knoblich J. A., Young P. and Schwamborn J. C. (2011) The E3-ubiquitin ligase TRIM2 regulates neuronal polarization. J. Neurochem. 117, 2937.
  • Kim J., Inoue K., Ishii J., Vanti W. B., Voronov S. V., Murchison E., Hannon G. and Abeliovich A. (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317, 12201224.
  • Kosik K. S. (2006) The neuronal microRNA system. Nat. Rev. Neurosci. 7, 911920.
  • Krek A., Grun D., Poy M. N. et al. (2005) Combinatorial microRNA target predictions. Nat. Genet. 37, 495500.
  • Lam Y. C., Bowman A. B., Jafar-Nejad P. et al. (2006) ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127, 13351347.
  • Lau P. and de Strooper B. (2010) Dysregulated microRNAs in neurodegenerative disorders. Semin. Cell Dev. Biol.. 21, 768773.
  • Lee S. T., Chu K., Im W. S. et al. (2011) Altered microRNA regulation in Huntington's disease models. Exp. Neurol. 227, 172179.
  • Leone S., Mutti C., Kazantsev A., Sturlese M., Moro S., Cattaneo E., Rigamonti D. and Contini A. (2008) SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease. Bioorg. Med. Chem. 16, 56955703.
  • Lintas C., Sacco R., Garbett K., et al. (2009) Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression. Mol. Psychiatry 14, 705718.
  • Luthi-Carter R., Strand A., Peters N. L. et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9, 12591271.
  • Luthi-Carter R., Strand A. D., Hanson S. A. et al. (2002) Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 11, 19271937.
  • Mason S., Piper M., Gronostajski R. M. and Richards L. J. (2009) Nuclear factor one transcription factors in CNS development. Mol. Neurobiol. 39, 1023.
  • Meng X., Kanwar N., Du Q., Goping I. S., Bleackley R. C. and Wilkins J. A. (2009) PPP1R9B (Neurabin 2): involvement and dynamics in the NK immunological synapse. Eur. J. Immunol. 39, 552560.
  • Miller L. C., Swayne L. A., Chen L., Feng Z. P., Wacker J. L., Muchowski P. J., Zamponi G. W. and Braun J. E. (2003) Cysteine string protein (CSP) inhibition of N-type calcium channels is blocked by mutant huntingtin. J. Biol. Chem. 278, 5307253081.
  • Nakaya N., Lee H. S., Takada Y., Tzchori I. and Tomarev S. I. (2008) Zebrafish olfactomedin 1 regulates retinal axon elongation in vivo and is a modulator of Wnt signaling pathway. J. Neurosci. 28, 79007910.
  • Packer A. N., Xing Y., Harper S. Q., Jones L. and Davidson B. L. (2008) The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 28, 1434114346.
  • Pahnke J., Mix E., Knoblich R. et al. (2004) Overexpression of glial cell line-derived neurotrophic factor induces genes regulating migration and differentiation of neuronal progenitor cells. Exp. Cell Res. 297, 484494.
  • Pulido R., Krueger N. X., Serra-Pages C., Saito H. and Streuli M. (1995a) Molecular characterization of the human transmembrane protein-tyrosine phosphatase delta. Evidence for tissue-specific expression of alternative human transmembrane protein-tyrosine phosphatase delta isoforms. J. Biol. Chem. 270, 67226728.
  • Pulido R., Serra-Pages C., Tang M. and Streuli M. (1995b) The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1. Proc. Natl Acad. Sci. USA 92, 1168611690.
  • Rodrigues N. R., Theodosiou A. M., Nesbit M. A., Campbell L., Tandle A. T., Saranath D. and Davies K. E. (2000) Characterization of Ngef, a novel member of the Dbl family of genes expressed predominantly in the caudate nucleus. Genomics 65, 5361.
  • Runne H., Régulier E., Kuhn A., Zala D., Gokce O., Perrin V., Sick B., Aebischer P., Déglon N. and Luthi-Carter R. (2008) Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J. Neurosci. 28, 97239731.
  • Sinha M., Ghose J., Das E. and Bhattarcharyya N. P. (2011) Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP. Biochem. Biophys. Res. Commun. 396, 742747.
  • Sudo K., Ito H., Iwamoto I., Morishita R., Asano T. and Nagata K. (2006) Identification of a cell polarity-related protein, Lin-7B, as a binding partner for a Rho effector, Rhotekin, and their possible interaction in neurons. Neurosci. Res. 56, 347355.
  • Tang X., Guilherme A., Chakladar A., Powelka A. M., Konda S., Virbasius J. V., Nicoloro S. M., Straubhaar J. and Czech M. P. (2006) An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARgamma, adipogenesis, and insulin-responsive hexose transport. Proc. Natl Acad. Sci. USA 103, 20872092.
  • Thomson J. M., Parker J., Perou C. M. and Hammond S. M. (2004) A custom microarray platform for analysis of microRNA gene expression. Nat. Methods 1, 4753.
  • Trettel F., Rigamonti D., Hilditch-Maguire P., Wheeler V. C., Sharp A. H., Persichetti F., Cattaneo E. and MacDonald M. E. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9, 27992809.
  • Trivedi S. and Ramakrishna G. (2009) miRNA and neurons. Int. J. Neurosci. 119, 19952016.
  • Trottier Y., Lutz Y., Stevanin G., Imbert G., Devys D., Cancel G., Saudou F., Weber C., David G. and Tora L. (1995) Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378, 403406.
  • Wallace M. J., Fladd C., Batt J. and Rotin D. (1998) The second catalytic domain of protein tyrosine phosphatase delta (PTP delta) binds to and inhibits the first catalytic domain of PTP sigma. Mol. Cell. Biol. 18, 26082616.
  • Wang K. C., Koprivica V., Kim J. A., Sivasankaran R., Guo Y., Neve R. L. and He Z. (2002) Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 417, 941944.
  • Yu Z. X., Li S. H., Evans J., Pillarisetti A., Li H. and Li X. J. (2003) Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 23, 21932202.
  • Zuccato C., Valenza M. and Cattaneo E. (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 90, 905981.